NCT07794969Not yet recruiting
Pancreatic Cancer Lifestyle Evolution And Resistance
Decoding Environmental Drivers of Adaptive Evolution and Chemotherapy Resistance in Advanced Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 31 Aug 2026
Brief summary (registry, in English)
Advanced PDAC patients undergo polychemotherapy, yet responses are highly variable. Transcriptome signatures are emerging as key predictors of treatment response. However, PDAC adapts across sites (primary vs. metastases) and evolves under treatment pressure (pre- vs. post-chemotherapy). Moreover, common environmental pollutants, like smoking and microplastics, contribute to carcinogenesis, yet their impact on PDAC evolution and treatment response remains unclear. To fill these gaps, the CLEAR project aims at investigating: 1. transcriptome patterns linked to treatment response; 2. effects of smoking and microplastic exposure on treatment outcomes; 3. PDAC evolution across organ sites and under chemotherapy. These studies will help uncover biomarkers and factors shaping disease progression, hence paving the ground for personalized therapies.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 26 Aug 2026
- Start date
- 31 Oct 2026
- Primary completion date
- 31 Oct 2029
- Lead sponsor
- IRCCS San Raffaele
- Diseases
- Pancreatic cancer
- NCT number
- NCT07794969
What you commit to
- Study type: Observational
- Planned participants: 150
- From 31 Oct 2026 to the primary completion date, 31 Oct 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Cytology positive for malignancies other than PDAC
Other
- Patients not willing to sign informed consent
- Pregnancy and breastfeeding
- Patients who have not performed biopsy for safety or technical reasons
- Patients unfit for polychemotherapy
Who the study is looking for
- Age = 18 years
- Willing to sign informed consent
- Patient with CT scan or MRI or EUS with a lesion suspect of PDAC at any clinical stage
- Patients considered fit to receive polychemotherapy with either mFOL, NG or PAXG.
- Patients primarily followed at HSR
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.